Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

678
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
678
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

734
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
734
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

903
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
903
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

854
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
854

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Characterization of the stages of chronic liver disease based on plasma proteins involved in systemic inflammation.

Revista espanola de enfermedades digestivas·2026
Same author

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Inflammatory bowel diseases·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

The Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn's Disease and Ulcerative Colitis)-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry.

Journal of Crohn's & colitis·2026

Related Experiment Video

Updated: Apr 21, 2026

Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

16.7K

Optimizing post-operative Crohn's disease treatment.

Eugeni Domènech1, Míriam Mañosa1, Triana Lobatón1

  • 1IBD Unit, Gastroenterology Department, Hospital Universitari Germans Trias i Pujol and Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, Spain.

Annals of Gastroenterology
|October 22, 2014
PubMed
Summary

Post-operative recurrence (POR) is common in Crohn's disease patients after intestinal resection. Early intervention with thiopurine or anti-TNF therapy may prevent recurrence, but optimal strategies require further research.

Keywords:
Crohn’s diseaseanti-TNFcalprotectinileocolonoscopyrecurrencethiopurines

More Related Videos

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

12.8K
Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

240

Related Experiment Videos

Last Updated: Apr 21, 2026

Murine Ileocolic Bowel Resection with Primary Anastomosis
08:49

Murine Ileocolic Bowel Resection with Primary Anastomosis

Published on: October 29, 2014

16.7K
Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

12.8K
Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

240

Area of Science:

  • Gastroenterology and Immunology
  • Surgical Gastroenterology

Background:

  • Crohn's disease often necessitates intestinal resection, yet post-operative recurrence (POR) affects up to 80% of patients within a year without preventive measures.
  • Active smoking is the sole confirmed risk factor for early POR, highlighting the need for targeted interventions.

Approach:

  • This review examines current evidence on preventing and managing Crohn's disease POR following resectional surgery.
  • Focuses on the efficacy of thiopurine and anti-tumor necrosis factor (anti-TNF) therapies in managing recurrent intestinal lesions.

Key Points:

  • Endoscopic monitoring within 6-12 months post-surgery is recommended to detect POR.
  • Thiopurine and anti-TNF therapies show promise for preventing or treating recurrent Crohn's disease lesions.
  • Optimal drug selection and monitoring frequency for POR remain undetermined.

Conclusions:

  • Despite advancements, intestinal resection is frequent in Crohn's disease, with high rates of post-operative recurrence.
  • Further research is crucial to define personalized therapeutic strategies and monitoring protocols for preventing and managing POR.